Radiopharmaceutical theranostics involves a combined medical approach that integrates therapeutics (treatment) and diagnostics (diagnosis) through the utilization of radiopharmaceuticals. These substances are employed for patient diagnosis, therapy, and personalized management.
The primary product categories within radiopharmaceutical theranostics include alpha emitters, beta emitters, and positron emission tomography (PET) tracers. Alpha emitters are radioactive substances emitting alpha particles, characterized by high-energy particles consisting of two protons and two neutrons. Various sources for these include nuclear reactors and cyclotrons, and the diverse radioisotopes encompass technetium-99, gallium-68, iodine-131, iodine-123, 18F, Y-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, among others. These radiopharmaceuticals find applications in oncology, cardiology, neurology, and other medical indications, and are utilized by various end-users, including hospitals, diagnostic imaging centers, academic and research institutes, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The radiopharmaceutical theranostics market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceutical theranostics market statistics, including radiopharmaceutical theranostics industry global market size, regional shares, competitors with a radiopharmaceutical theranostics market share, detailed radiopharmaceutical theranostics market segments, market trends, and opportunities, and any further data you may need to thrive in the radiopharmaceutical theranostics industry. This radiopharmaceutical theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The radiopharmaceutical theranostics market size has grown rapidly in recent years. It will grow from $2.88 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to radiopharmaceutical development, clinical research advances, investment in research, regulatory approval, and nuclear medicine progress.
The radiopharmaceutical theranostics market size is expected to see rapid growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to biomarker discovery and validation, genomic and proteomic technologies, precision radiotherapy development, interdisciplinary collaborations, patient advocacy and support. Major trends in the forecast period include ethical and legal considerations, telemedicine in theranostics, patient-centric care, radiopharmaceutical customization, and nano-theranostics development.
The forecast of 15.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of lutetium-177 and gallium-68 PSMA kits sourced from Belgium and Australia, exacerbating nuclear medicine expenses and delaying personalized cancer treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The radiopharmaceutical theranostics market is poised for growth, driven by the increasing incidence of cancer. Cancer, characterized by abnormal cell growth that can invade and spread, necessitates targeted and personalized approaches for effective treatment. Radiopharmaceutical theranostics plays a crucial role in cancer treatment, offering precision and personalized solutions. In the US alone, the American Cancer Society estimates that 1.9 million new cancer cases may be diagnosed in 2023, resulting in approximately 609,820 deaths. The majority of these diagnoses, 88%, are expected to be in individuals aged 50 and above. The rising prevalence of cancer is a key factor fueling the expansion of the radiopharmaceutical theranostics market.
Increasing healthcare expenditure is playing a significant role in the growth of the radiopharmaceutical theranostics market in the future. Supportive government initiatives, along with grants and funding for research and development in the area of radiopharmaceutical theranostics, promote innovation and facilitate the commercialization of new products. For example, in October 2024, the Centers for Medicare & Medicaid Services, a federal agency in the US, reported that prescription drug spending increased by 8.4%, reaching $405.9 billion in 2022, surpassing the 6.8% growth seen in 2021. Consequently, the rising healthcare expenditure is expected to propel the radiopharmaceutical theranostics market.
Leading companies in the radiopharmaceutical theranostics market are embracing a strategic partnership model to create innovative therapies. These collaborations allow radiopharmaceutical theranostics firms to pool resources and expertise, improve research and development capabilities, broaden market reach, and speed up commercialization, ultimately fostering innovation and growth within the industry. For example, in March 2023, Radiopharm Theranostics, a biotechnology company based in Australia, formed a partnership with Pharma15 Corporation, a US-based venture, to develop next-generation therapeutic radiopharmaceuticals aimed at prostate cancer. The focus is on overcoming resistance to current PSMA-targeted therapies while improving selectivity to reduce toxicity in healthy tissues.
Companies operating in the radiopharmaceutical theranostics market are also focusing on the development of theranostics for cancer treatment. Theranostic approaches aim to provide targeted therapies and diagnostic solutions for rare diseases, particularly for patients with limited treatment options such as cancer. In November 2023, GE HealthCare Technologies Inc. launched theranostic solutions for cancer, marking a significant stride in precision medicine. Theranostics utilizes therapeutic agents in conjunction with imaging technology to identify and target cancer cells for destruction.
In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company, acquired Pharma15 Corporation for $4 million. This strategic move positions Radiopharm to explore next-generation radiopharmaceuticals for prostate cancer treatment, surpassing PSMA-based therapies, and advancing innovative solutions for patients. Pharma15 Corporation, a US-based pharmaceutical company, specializes in radio-immuno-theranostics platforms and pharmaceutical products' development, aligning with Radiopharm's focus on advancing radiopharmaceutical products.
Major companies operating in the radiopharmaceutical theranostics market include Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.
North America was the largest region in the radiopharmaceutical theranostics market in 2024. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the radiopharmaceutical theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The radiopharmaceutical theranostics market includes revenues earned by providing genetic testing, targeted therapy services, contract development, and manufacturing services, consultation and interpretation, and personalized therapeutic interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Radiopharmaceutical Theranostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on radiopharmaceutical theranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for radiopharmaceutical theranostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radiopharmaceutical theranostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product Type: Alpha Emitters; Beta Emitters; Positron Emission Tomography (PET) Tracers
- 2) By Source: Nuclear Reactors; Cyclotrons
- 3) By Radioisotope: Technetium-99; Gallium-68; Iodine-131; Iodine-123; 18F; Y-90; Lutetium (Lu) 177; Copper (Cu) 67; Copper (Cu) 64; Other Radioscopes
- 4) By Indication: Oncology; Cardiology; Neurology; Other Indications
- 5) By End User: Hospitals; Diagnostic Imaging Centers; Academic And Research Institutes; Other End Users
- Subsegments:
- 1) By Alpha Emitters: Actinium-225; Radium-223; Bismuth-213; Other Alpha-Emitting Radiopharmaceuticals
- 2) By Beta Emitters: Iodine-131; Lutetium-177; Yttrium-90; Other Beta-Emitting Radiopharmaceuticals
- 3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG); Gallium-68; Carbon-11; Other PET Tracers
- Companies Mentioned: Cardinal Health Inc.; GE HealthCare Technologies Inc.; Bayer AG; China Grand Pharmaceutical & Healthcare.; Lantheus Medical Imaging Inc.; Curium Pharma; Advanced Accelerator Applications; Telix Pharmaceuticals Ltd.; Bracco Imaging S.p.A; NTP Radioisotopes SOC Ltd.; Navidea Biopharmaceuticals Inc.; Jubilant DraxImage Inc.; NorthStar Medical Radioisotopes LLC; Blue Earth Diagnostics Ltd.; Precirix NV; SpectronRx; Viewpoint Molecular Targeting Inc.; NuView Life Sciences; Alpha-9 Theranostics Inc.; RadioMedix Inc; RayzeBio Inc; Fusion Pharmaceuticals Inc; Actinium Pharmaceuticals Inc.; Eckert & Ziegler Strahlen- und Medizintechnik AG; Ariceum Therapeutics GmbH; Radiopharm Theranostics Ltd; Ratio Therapeutics Inc; Primo Biotechnology; Bivision Biomedical Technology (Nanjing) Co. Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Radiopharmaceutical Theranostics Market Characteristics
3. Radiopharmaceutical Theranostics Market Trends And Strategies
4. Radiopharmaceutical Theranostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Radiopharmaceutical Theranostics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Radiopharmaceutical Theranostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Radiopharmaceutical Theranostics Market Growth Rate Analysis
- 5.4. Global Radiopharmaceutical Theranostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Radiopharmaceutical Theranostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Radiopharmaceutical Theranostics Total Addressable Market (TAM)
6. Radiopharmaceutical Theranostics Market Segmentation
- 6.1. Global Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Alpha Emitters
- Beta Emitters
- Positron Emission Tomography (PET) Tracers
- 6.2. Global Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nuclear Reactors
- Cyclotrons
- 6.3. Global Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Technetium-99
- Gallium-68
- Iodine-131
- Iodine-123
- 18F
- Y-90
- Lutetium (Lu) 177
- Copper (Cu) 67
- Copper (Cu) 64
- Other Radioscopes
- 6.4. Global Radiopharmaceutical Theranostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oncology
- Cardiology
- Neurology
- Other Indications
- 6.5. Global Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Diagnostic Imaging Centers
- Academic And Research Institutes
- Other End Users
- 6.6. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Alpha Emitters, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Actinium-225
- Radium-223
- Bismuth-213
- Other Alpha-Emitting Radiopharmaceuticals
- 6.7. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Beta Emitters, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Iodine-131
- Lutetium-177
- Yttrium-90
- Other Beta-Emitting Radiopharmaceuticals
- 6.8. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Positron Emission Tomography (PET) Tracers, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Fluorodeoxyglucose (FDG)
- Gallium-68
- Carbon-11
- Other PET Tracers
7. Radiopharmaceutical Theranostics Market Regional And Country Analysis
- 7.1. Global Radiopharmaceutical Theranostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Radiopharmaceutical Theranostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Radiopharmaceutical Theranostics Market
- 8.1. Asia-Pacific Radiopharmaceutical Theranostics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Radiopharmaceutical Theranostics Market
- 9.1. China Radiopharmaceutical Theranostics Market Overview
- 9.2. China Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Radiopharmaceutical Theranostics Market
- 10.1. India Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Radiopharmaceutical Theranostics Market
- 11.1. Japan Radiopharmaceutical Theranostics Market Overview
- 11.2. Japan Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Radiopharmaceutical Theranostics Market
- 12.1. Australia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Radiopharmaceutical Theranostics Market
- 13.1. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Radiopharmaceutical Theranostics Market
- 14.1. South Korea Radiopharmaceutical Theranostics Market Overview
- 14.2. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Radiopharmaceutical Theranostics Market
- 15.1. Western Europe Radiopharmaceutical Theranostics Market Overview
- 15.2. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Radiopharmaceutical Theranostics Market
- 16.1. UK Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Radiopharmaceutical Theranostics Market
- 17.1. Germany Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Radiopharmaceutical Theranostics Market
- 18.1. France Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Radiopharmaceutical Theranostics Market
- 19.1. Italy Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Radiopharmaceutical Theranostics Market
- 20.1. Spain Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Radiopharmaceutical Theranostics Market
- 21.1. Eastern Europe Radiopharmaceutical Theranostics Market Overview
- 21.2. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Radiopharmaceutical Theranostics Market
- 22.1. Russia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Radiopharmaceutical Theranostics Market
- 23.1. North America Radiopharmaceutical Theranostics Market Overview
- 23.2. North America Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Radiopharmaceutical Theranostics Market
- 24.1. USA Radiopharmaceutical Theranostics Market Overview
- 24.2. USA Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Radiopharmaceutical Theranostics Market
- 25.1. Canada Radiopharmaceutical Theranostics Market Overview
- 25.2. Canada Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Radiopharmaceutical Theranostics Market
- 26.1. South America Radiopharmaceutical Theranostics Market Overview
- 26.2. South America Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Radiopharmaceutical Theranostics Market
- 27.1. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Radiopharmaceutical Theranostics Market
- 28.1. Middle East Radiopharmaceutical Theranostics Market Overview
- 28.2. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Radiopharmaceutical Theranostics Market
- 29.1. Africa Radiopharmaceutical Theranostics Market Overview
- 29.2. Africa Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Radiopharmaceutical Theranostics Market Competitive Landscape And Company Profiles
- 30.1. Radiopharmaceutical Theranostics Market Competitive Landscape
- 30.2. Radiopharmaceutical Theranostics Market Company Profiles
- 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GE HealthCare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. China Grand Pharmaceutical & Healthcare. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Lantheus Medical Imaging Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Radiopharmaceutical Theranostics Market Other Major And Innovative Companies
- 31.1. Curium Pharma
- 31.2. Advanced Accelerator Applications
- 31.3. Telix Pharmaceuticals Ltd.
- 31.4. Bracco Imaging S.p.A
- 31.5. NTP Radioisotopes SOC Ltd.
- 31.6. Navidea Biopharmaceuticals Inc.
- 31.7. Jubilant DraxImage Inc.
- 31.8. NorthStar Medical Radioisotopes LLC
- 31.9. Blue Earth Diagnostics Ltd.
- 31.10. Precirix NV
- 31.11. SpectronRx
- 31.12. Viewpoint Molecular Targeting Inc.
- 31.13. NuView Life Sciences
- 31.14. Alpha-9 Theranostics Inc.
- 31.15. RadioMedix Inc
32. Global Radiopharmaceutical Theranostics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Radiopharmaceutical Theranostics Market
34. Recent Developments In The Radiopharmaceutical Theranostics Market
35. Radiopharmaceutical Theranostics Market High Potential Countries, Segments and Strategies
- 35.1 Radiopharmaceutical Theranostics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Radiopharmaceutical Theranostics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Radiopharmaceutical Theranostics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
